AlTorress

CORT, MACD Histogram just turned positive

Long
NASDAQ:CORT   Corcept Therapeutics Incorporated
This is a Bullish indicator signaling CORT's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron's A.I. dvisor identified 48 similar cases where CORT's MACD histogram became positive, and 42 of them led to successful outcomes. Odds of Success: 88%. Current price $30.80 is above $27.05 the highest support line found by Tickeron A.I. Throughout the month of 01/06/21 - 02/08/21, the price experienced a +16% Uptrend. During the week of 02/01/21 - 02/08/21, the stock enjoyed a +4% Uptrend growth.

Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on January 12, 2021. You may want to consider a long position or call options on CORT as a result. Tickeron A.I. detected that in 61 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

CORT moved above its 50-day Moving Average on November 02, 2020 date and that indicates a change from a downward trend to an upward trend.

The 10-day Moving Average for CORT crossed bullishly above the 50-day moving average on November 12, 2020. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +5.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 291 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. Tickeron A.I. detected that in 221 of 260 cases where CORT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.